このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Acelyrin マネジメント

マネジメント基準チェック /04

Acelyrin'sの CEO はMina Kimで、 May2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.025%を直接所有しており、その価値は$ 104.14K 。経営陣と取締役会の平均在任期間はそれぞれ0.7年と1.8年です。

主要情報

Mina Kim

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.02%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	2yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Mina Kim (50 yo)

less than a year

在職期間

Ms. Mina Kim joined and served as a Chief Legal Officer at Zymergen, Inc. since January 2020 until August 2022 and also serves as its Corporate Secretary. She served as the Chief Legal and Administrative O...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Melanie Gloria	Chief Operating Officer	2.8yrs	US$11.48m	0.13% $ 642.3k
Mina Kim	CEO & Director	less than a year	データなし	0.025% $ 121.9k
Gilbert Labrucherie	CFO & Chief Business Officer	less than a year	データなし	0.047% $ 231.8k
Tyler Marciniak	Head of Investor Relations & Communications	2.3yrs	データなし	データなし
Sanam Pangali	Chief Legal Officer & Head of People	less than a year	データなし	0.074% $ 365.6k
Suzy Buckhalter	Senior Director of Finance & Accounting	no data	データなし	データなし
Kenneth Lock	Chief Commercial Officer	1.2yrs	データなし	データなし
Shephard Mpofu	Chief Medical Officer	less than a year	データなし	データなし
Patricia Turney	Chief Technical Operations Officer	less than a year	データなし	データなし

1.0yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: SLRNの経営陣は経験豊富とはみなされません ( 0.7年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Mina Kim	CEO & Director	less than a year	データなし	0.025% $ 121.9k
Bruce Cozadd	Independent Chairman	2.5yrs	US$390.49k	0% $ 0
Beth Seidenberg	Independent Director	3.9yrs	US$349.51k	0.060% $ 295.8k
Lynn Tetrault	Independent Director	less than a year	US$482.26k	0% $ 0
C. Machado	Independent Director	3.4yrs	US$402.20k	0.015% $ 72.3k
Alan Colowick	Independent Director	2.8yrs	データなし	データなし
Dawn Svoronos	Independent Director	1.8yrs	US$376.67k	0.015% $ 74.0k
Daniel Becker	Independent Director	2yrs	US$351.09k	0.0030% $ 14.8k
Henry Gosebruch	Independent Director	1.5yrs	US$1.02m	0.050% $ 246.5k

2.0yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: SLRNの取締役会は経験豊富ではない ( 1.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Acelyrin マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Acelyrin, Inc. Announces CEO Changes

Acelyrin, Inc., Annual General Meeting, Jun 07, 2024

Chief Medical Officer notifies of intention to sell stock

Co-Founder recently sold US$119k worth of stock

Acelyrin, Inc. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

High number of new and inexperienced directors

Recent updates

Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch

New minor risk - Shareholder dilution

Price target decreased by 47% to US$12.00

ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa

Acelyrin, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Companies Like Acelyrin (NASDAQ:SLRN) Are In A Position To Invest In Growth

New major risk - Revenue and earnings growth

ACELYRIN, Inc. Announces Positive 16-Week Data from its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to Be Shared During Late-Breaking Oral Presentation at EULAR 2024

New major risk - Revenue and earnings growth

Price target decreased by 8.3% to US$22.17

Acelyrin, Inc. Announces CEO Changes

Acelyrin, Inc. to Report Q1, 2024 Results on May 13, 2024

Acelyrin, Inc., Annual General Meeting, Jun 07, 2024

New major risk - Revenue and earnings growth

Chief Medical Officer notifies of intention to sell stock

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-Of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

Acelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritis

Acelyrin, Inc. Announces Long-Term 32-Week Data from the Phase 2B Trial of Izokibep in Hidradenitis Suppurativa

New minor risk - Insider selling

Co-Founder recently sold US$119k worth of stock

Acelyrin, Inc. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

High number of new and inexperienced directors

Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Acelyrin, Inc

Acelyrin, Inc. Appoints Lynn Tetrault to Board of Directors

Acelyrin, Inc. Provides Update on Izokibep Clinical Development Program

Acelyrin, Inc. Provides Update on Izokibep Clinical Development Program

Equity Alert: Rosen Encourages Acelyrin, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Equity Alert: Rosen Encourages Acelyrin, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Acelyrin, Inc. Appoints Patricia Turney as Chief Technical Operations Officer

Acelyrin, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Financial data availability

Acelyrin, Inc. Appoints Shephard Mpofu as Senior Vice President of Development

Acelyrin, Inc. Appoints Gil Labrucherie as Full Time Chief Financial Officer

New major risk - Revenue and earnings growth

ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer

New major risk - Financial position

Acelyrin, Inc. has completed an IPO in the amount of $540 million.

No independent directors

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04